A friend of mine, a 34-year-old software developer in Austin, texted me a photo of his shower drain last October. He’d been on strict keto for about nine weeks, down 18 pounds, feeling great, and then suddenly his hair started coming out in clumps that clogged the drain screen every morning. “Am I going bald or is this the diet?” was the question. It’s a question a lot of people are asking right now, and the answer is more nuanced than either the keto evangelists or the hair-loss panic forums will tell you.
In short, ketogenic and other very low-carb diets can absolutely trigger a type of temporary shedding called telogen effluvium. This is not the same thing as pattern hair loss (androgenetic alopecia), and conflating the two leads people to either ignore a real problem or panic about a temporary one. Pulling those apart is what this article is actually about.
What Keto Shedding Is (and What It Isn’t)
Any significant dietary change, whether it’s keto, severe caloric restriction, very low protein intake, or rapid weight loss of any kind, can push a larger-than-normal percentage of hair follicles from the growth phase (anagen) into the resting phase (telogen). Two to three months later, those resting hairs fall out. This is telogen effluvium, and it typically resolves on its own within six to nine months once the body adjusts or the stressor passes.
The biology here is pretty straightforward. Hair follicles are metabolically expensive tissue. When the body senses a significant shift in energy availability, hormonal milieu, or nutrient supply, it triages. Hair is not essential for survival, so it gets deprioritized. Keto does several things simultaneously that can trigger this: rapid caloric deficit, a dramatic shift in macronutrient ratios, potential drops in insulin and IGF-1 signaling, and sometimes inadvertent protein or micronutrient insufficiency.
Here’s what it is not: pattern hair loss. Androgenetic alopecia is a genetically driven, DHT-mediated process that works on an entirely different timeline and mechanism. If you’re losing hair at the temples and crown in a recognizable pattern, keto didn’t cause that. It may have unmasked it, or you may have noticed it because you started paying closer attention to your body, but the process was already underway.
The Hamilton-Norwood Framework and Why It Matters Here
James Hamilton’s 1951 paper in the Annals of the New York Academy of Sciences first established the link between androgens and male pattern hair loss. His observation was elegant: men castrated before puberty simply didn’t develop the characteristic recession and crown thinning. Androgens were required.
O’Tar Norwood expanded Hamilton’s original three-stage framework into the seven-stage classification system (with variant subtypes, including the Type A front-to-back pattern) in his 1975 Southern Medical Journal paper. That system has held up for more than 70 years, partly because it balances clinical precision with ease of use. Newer systems like the 2007 BASP classification exist but haven’t displaced Norwood in everyday dermatology practice.
Why does this matter for someone worried about keto-related shedding? Because the first diagnostic question is always: what kind of hair loss are you actually dealing with? Telogen effluvium is diffuse, meaning it thins everywhere roughly equally. Pattern loss follows the Norwood map, concentrating at the temples, hairline, and vertex. Distinguishing the two determines whether you need to adjust your diet or start a medication.
The Androgen Biology Underneath Pattern Loss
If your shedding does turn out to be pattern loss (which keto didn’t cause, but which you might be noticing for the first time), the mechanism is worth understanding.
Dihydrotestosterone (DHT), produced from testosterone by the enzyme 5-alpha reductase, binds to androgen receptors in genetically susceptible follicles and progressively shortens the growth phase. Over successive cycles, the follicle miniaturizes. Terminal hairs become vellus hairs, thin and short and nearly invisible. This is follicular miniaturization, and it’s the hallmark finding on trichoscopy.
The genetics are polygenic. The androgen receptor gene on the X chromosome gets the most attention (hence the “look at your mother’s father” folk wisdom), but paternal-side genes and multiple autosomal loci contribute meaningfully. Family history is a rough guide, not a blueprint.
Two FDA-approved pharmacologic interventions exploit this pathway. Finasteride blocks the type II isoform of 5-alpha reductase, lowering scalp DHT. Dutasteride (approved for benign prostatic hypertrophy, used off-label for hair) blocks both type I and type II isoforms and lowers DHT more aggressively, with correspondingly larger improvements in head-to-head trials (Olsen et al., JAAD, 2006).
How Dermatologists Actually Work This Up
The American Academy of Dermatology’s clinical guidelines lay out a structured approach: patient history, family history, scalp exam, trichoscopy, and selective lab work.
Trichoscopy is the underappreciated workhorse here. Under dermoscopy, androgenetic alopecia shows caliber variability of 20% or more among hair shafts, yellow dots (empty follicular ostia), and density loss in affected zones with preservation of the occipital donor area. Telogen effluvium, by contrast, shows diffuse thinning without the same degree of diameter variability.
Lab testing is selective, not shotgun. Ferritin, TSH, vitamin D, and CBC are reasonable when telogen effluvium is suspected. The AAD does not recommend routine androgen panels in men with classic pattern loss because the diagnosis is clinical. (This is a point I wish more direct-to-consumer hair companies were honest about. A testosterone level tells you almost nothing useful in a man with obvious Norwood III loss.)
Standardized photography, front, top, sides, and back at consistent distance and lighting, is boring but essential. Without it, you’re relying on memory and the mirror, both of which are unreliable over months.
Treatment: What Actually Works, What It Costs
Oral finasteride 1 mg daily has the deepest evidence base. The original five-year randomized trial (JAAD, 2002) showed sustained improvements in hair count versus placebo. Sexual side effects affect a small percentage and are generally reversible on discontinuation.
Topical minoxidil 5%, applied twice daily, prolongs anagen through mechanisms that probably involve potassium channel opening and vasodilation. Response emerges at three to six months in roughly 40 to 60 percent of users. A subset of patients lack sufficient sulfotransferase activity to convert minoxidil to its active form, which partly explains nonresponse.
Low-dose oral minoxidil (0.25 to 5 mg daily) gained significant traction after Vañó-Galván and colleagues published safety data on 1,404 patients in JAAD in 2021. The side-effect profile at low doses is more manageable than original cardiovascular formulations, though periorbital edema and hypertrichosis crop up.
PRP runs $500 to $1,500 per session, typically three to four sessions in year one. JAMA Dermatology has published smaller randomized trials with positive but variable findings. Reasonable as an adjunct, not a substitute.
Hair transplantation (FUE or FUT) costs $4 to $10 per graft in the US, putting a typical 2,500 to 3,500 graft case at $10,000 to $35,000. Turkish clinics offer similar graft counts for $2,000 to $5,000, reflecting labor cost differences more than quality differences per se (though quality variation is real and wide).
The boring truth on cost: generic finasteride runs $10 to $25 per month. Generic topical minoxidil, $10 to $30. These are cheap medications. The expensive part is the transplant or the years of PRP sessions. Insurance covers none of it for pattern loss (cosmetic classification), though HSAs and FSAs may cover prescribed medications.
Lifestyle Factors: Separating Signal from Noise
Smoking accelerates hair loss through microvascular damage, oxidative stress, and effects on circulating androgens. Cross-sectional studies in matched populations show higher rates of androgenetic alopecia in smokers.
Iron deficiency (ferritin below 30 ng/mL in women, below 50 ng/mL when hair loss is the concern) contributes to telogen effluvium. Repletion helps. Supplementation in iron-replete patients does not.
Severe acute stress triggers telogen effluvium two to three months downstream. This is well documented and resolves within six to nine months if the stressor abates. It may also unmask underlying pattern loss that was previously subclinical.
Anabolic steroid use accelerates pattern loss in genetically susceptible men, with effects that may not fully reverse after stopping. Sleep deprivation contributes to elevated cortisol and disrupted follicle cycling, though the clinical magnitude in otherwise healthy adults is small.
And diet? Severe restriction and rapid weight loss reliably produce telogen effluvium. Keto falls into this category for many people, especially in the first two to three months of aggressive caloric deficit. For this deep dive into how to track whether your shedding is diet-related or something else, photographic staging examples make the comparison concrete.
When You Actually Need a Dermatologist in the Room
Self-management is reasonable for straightforward cases. But several situations call for an in-person evaluation:
Sudden, diffuse shedding within the last six months (telogen effluvium that needs workup, not just pattern loss meds). Patchy loss with smooth bald spots (alopecia areata, an autoimmune condition with a different treatment pathway). Scalp pain, burning, redness, scarring (possible lichen planopilaris, frontal fibrosing alopecia, or central centrifugal cicatricial alopecia, all of which require prompt diagnosis before permanent follicular destruction). Hair loss in women with menstrual irregularities, acne, or hirsutism (warrants endocrine evaluation for PCOS). Rapid progression of more than one Norwood stage per year in a young patient. Failure to respond to 12 months of documented standard therapy.
The AAD’s position is straightforward: any progressive hair loss that concerns the patient is a legitimate reason for consultation.
FAQs
What is shock loss after a hair transplant?
Shock loss is temporary shedding of native or transplanted hairs in the weeks after surgery. It typically resolves over three to six months as follicles cycle back into the growth phase.
Can pattern hair loss be reversed?
Partially, in some patients, with early treatment. Combination finasteride and minoxidil started before substantial follicular dropout offers the best chance. Late-stage loss with extensive miniaturization is generally not reversible with medical therapy alone.
Do biotin and collagen supplements help with hair loss?
In patients without documented deficiency, the evidence is weak. Biotin also interferes with several common laboratory tests, including thyroid function and troponin assays, which can lead to false readings.
Does minoxidil work for everyone?
It produces visible improvement in roughly 40 to 60 percent of users in randomized trials, with response typically appearing at three to six months. Nonresponse is partly explained by individual variation in sulfotransferase enzyme activity.
Is the Norwood scale used for women?
No. Female pattern hair loss is typically classified using the Ludwig or Savin scales, which capture the diffuse central thinning pattern more common in women.
Is oral minoxidil better than topical?
Low-dose oral minoxidil produces comparable effects with better adherence in many patients. The choice depends on side-effect tolerance and individual preference, and should involve a prescribing clinician.
Can keto cause permanent hair loss?
Keto-related shedding is telogen effluvium, which is temporary. It does not destroy follicles. If your hair loss continues beyond nine to twelve months or follows a pattern distribution (temples, crown), you’re likely dealing with androgenetic alopecia, which predates the diet.
References
- Hamilton JB. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci. 1951;53(3):708-728.
- Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359-1365.
- Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men: short version. J Eur Acad Dermatol Venereol. 2018;32(1):11-22.
- American Academy of Dermatology Association. Hair loss: diagnosis and treatment. AAD clinical guidance.
- Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss. J Am Acad Dermatol. 2006;55(6):1014-1023.
- Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104-109.
- Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651.
- Gentile P, Garcovich S. Systematic review of platelet-rich plasma use in androgenetic alopecia compared with minoxidil, finasteride, and adult stem cell-based therapy. Int J Mol Sci. 2020;21(8):2702.
- Kassira S, Korta DZ, Chapman LW, Dann F. Frontal fibrosing alopecia: a review. J Am Acad Dermatol. 2017;77(2):209-212.
- Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777-2786.
Educational content, not medical advice. This article summarizes peer-reviewed sources and clinical guidelines for general informational purposes and does not constitute medical advice, diagnosis, or treatment. Hair loss has multiple possible causes, and an in-person dermatology evaluation is the appropriate starting point for any individual case. Do not start, stop, or change medications based on this article.
Privacy framing for AI-based assessment tools: AI hair-loss screening tools such as Myhairline.ai analyze user-submitted photos using MediaPipe Face Mesh 468-landmark detection. Photos are not stored, and no account is required. The AI output is educational, not diagnostic.
